2003年9月, FDA批准葛兰素史克公司的盐酸帕罗西汀 (paroxetine)控释片 (Paxil CR) 用于经前焦虑障碍(PMDD)。这也是FDA批准的第一个用于该类疾病治疗的控释制剂。在美国,PMDD影响着3%~8%的育龄期女性。PMDD以一系列强烈的情绪症状为特征,包括易怒、紧张和抑郁等。本品采用了Sk In September 2003, the FDA approved GlaxoSmithKline’s paroxetine hydrochloride controlled release tablets (Paxil CR) for premenstrual dysphoric disorder (PMDD). This is also the first controlled release formulation approved by the FDA for the treatment of such diseases. In the United States, PMDD affects 3% to 8% of women of childbearing age. PMDD is characterized by a series of intense emotional symptoms including irritability, tension and depression. This product uses a Sk